The earnings call was predominantly positive, with significant regulatory progress and promising clinical data on TSHA-102 for Rett syndrome. The company is financially stable with a reduced net loss and decreased R&D expenses, although there was an increase in general and administrative costs.

Company Guidance -

Q2 2025

During the Taysha Gene Therapies First Quarter 2025 earnings call, the company provided significant updates on their TSHA-102 gene therapy program for Rett syndrome. The company announced the completion of dosing for 10 patients in Part A of their REVEAL Phase 1/2 trials, with six patients receiving a high dose of TSHA-102. Encouragingly, TSHA-102 was generally well-tolerated across both high and low dose cohorts with no treatment-related serious adverse events or dose-limiting toxicities as of April 10, 2025. Taysha highlighted their alignment with the FDA on key elements of their pivotal Part B trial design, which eliminates the need for a formal end-of-phase meeting, potentially expediting study initiation. Financially, the company reported a net loss of $21.5 million for Q1 2025, with $116.6 million in cash reserves expected to support operations into Q4 2026. Overall, Taysha expressed confidence in the therapeutic potential of TSHA-102 and its path towards regulatory approval.

Progress in TSHA-102 Gene Therapy Program

Significant regulatory and clinical progress with TSHA-102 for Rett syndrome, including FDA alignment on pivotal trial design without the need for an end-of-phase meeting.

Positive Clinical Data

TSHA-102 has shown early clinical improvements and functional gains in pediatric, adolescent, and adult patients with Rett syndrome, which are unlikely in the untreated population.

Strong Financial Position

Taysha has $116.6 million in cash and cash equivalents, with cash resources expected to support operations into the fourth quarter of 2026.

Decreased R&D Expenses

Research and development expenses decreased by $5.1 million compared to the prior year, driven by reduced GMP batch activities.

Taysha Gene Therapies (TSHA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TSHA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 12, 2025	2025 (Q2)	-0.08 / -	-0.09	―	―	―
May 15, 2025	2025 (Q1)	-0.09 / -0.08	-0.1	20.00% (+0.02)	―
Feb 26, 2025	2024 (Q4)	-0.08 / -0.07	0.255	-127.45% (-0.33)	―
Nov 13, 2024	2024 (Q3)	-0.09 / -0.10	-0.93	89.25% (+0.83)	―
Aug 12, 2024	2024 (Q2)	-0.16 / -0.09	-0.38	76.32% (+0.29)	―
May 14, 2024	2024 (Q1)	-0.11 / -0.10	-0.28	64.29% (+0.18)	―
Mar 19, 2024	2023 (Q4)	-0.11 / 0.26	-0.99	125.76% (+1.25)	―
Nov 14, 2023	2023 (Q3)	-0.17 / -0.93	-0.64	-45.31% (-0.29)	―
Aug 14, 2023	2023 (Q2)	-0.31 / -0.38	-0.84	54.76% (+0.46)	―
May 11, 2023	2023 (Q1)	-0.36 / -0.28	-1.31	78.63% (+1.03)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

TSHA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 15, 2025	$2.37	$2.56	+8.02%
Feb 26, 2025	$1.70	$1.62	-4.71%
Nov 13, 2024	$2.21	$2.27	+2.71%
Aug 12, 2024	$2.09	$2.04	-2.39%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Taysha Gene Therapies, Inc. (TSHA) report earnings?

Taysha Gene Therapies, Inc. (TSHA) is schdueled to report earning on Aug 12, 2025, After Close (Confirmed).

What is Taysha Gene Therapies, Inc. (TSHA) earnings time?

Taysha Gene Therapies, Inc. (TSHA) earnings time is at Aug 12, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is TSHA EPS forecast?

TSHA EPS forecast for the fiscal quarter 2025 (Q2) is -0.08.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing